

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

CHANGE OF VENUE OF THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 1, 2022

Reference is made to the circular (the “**Circular**”) and the notice of annual general meeting (the “**Notice**”) of Antengene Corporation Limited (the “**Company**”) both dated April 20, 2022, and the accompanying form of proxy (the “**Proxy Form**”) regarding the annual general meeting of the Company (the “**AGM**”) to be held on Wednesday, June 1, 2022 at 10:30 a.m. Capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Notice unless the context requires otherwise.

Due to the uncertainty of the COVID-19 epidemic situation in Shanghai and the possible epidemic controlling measures to be implemented, the Board hereby announces that the venue of the AGM will be changed to 40th Floor, Dah Sing Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong.

Save for the change of venue of the AGM, all information and contents set out in the Circular, the Notice and the Proxy Form remain unchanged. The Proxy Form remains valid for the AGM and the Shareholders are not required to re-submit the Proxy Form if they have already done so.

PRECAUTIONARY MEASURES AT THE AGM

In view of the ongoing COVID-19 pandemic, the Company will implement the following precautionary measures at the AGM to protect attending Shareholders, staff and stakeholders from the risk of infection, including the following:

- (i) The Company will take the body temperature of the intended attendees and refuse entry of those with a temperature of 37.4 degree Celsius or above.
- (ii) Attendees are requested to observe good personal hygiene at all times at the venue of the Meetings and alcohol rubs or hand sanitiser will be provided for use.
- (iii) Attendees must wear face-masks throughout the Meetings and sit at a distance from other attendees and those not wearing face-masks may be denied entry to the venue of the Meetings. Please note that no masks will be provided at the venue of the Meetings and attendees should bring and wear their own masks.
- (iv) No distribution of corporate gift or refreshment.

- (v) Attendees who do not comply with the precautionary measures (i) to (iii) above or been found to have the symptom(s) of an upper respiratory system disease or shall be quarantined may be denied entry to the venue of the Meetings at the absolute discretion of the Company as permitted by law.

Subject to the development of ongoing COVID-19 pandemic, the Company may be required to change the AGM arrangements at short notice. Shareholders should check the websites of the Company (www.antengene.com) and the Stock Exchange (www.hkexnews.hk) for further announcements and updates on the AGM arrangements. In addition, the Company reminds all Shareholders that physical attendance in person at the AGM is not necessary for the purpose of exercising voting rights.

The Company strongly encourages Shareholders, instead of attending the AGM in person, to appoint the Chairman of the AGM as their proxy to vote on the relevant resolutions at the AGM, by completing and returning the Proxy Form as previously advised. Shareholders who intend to attend the AGM in person are advised to pay attention to the above-mentioned change of venue.

The Company apologizes for any inconvenience caused and is grateful to the Shareholders' understanding.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, May 17, 2022

As at the date of this announcement, the Board comprises Dr. Jay Mei, Mr. John F. Chin, Dr. Kevin Patrick Lynch and Mr. Donald Andrew Lung as executive Directors; Mr. Yilun Liu and Dr. Kan Chen as non-executive Directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive Directors.